On October 2, the European Medicines Agency (EMA) adopted a new policy requiring drug companies to make public certain clinical data related to drug approvals. Starting on January 1, 2015, EMA will begin publishing trial data for companies that submit drugs for approval on or after that date. For medications already on the market that are approved for new indications, the rule takes effect next July. The agency hopes the new policy establishes increased confidence in the system and enables independent secondary analysis leading to public health benefits.